Genetic abnormalities assist in pathological diagnosis and EBV-positive cell density impact survival in Chinese angioimmunoblastic T-cell lymphoma patients.
Yunfei Shi, Haojie Wang, Yanfei Liu, Mengping Long, Ning Ding, Lan Mi, Yumei Lai, Lixin Zhou, Xinting Diao, Xianghong Li, Weiping Liu, Jun Zhu
{"title":"Genetic abnormalities assist in pathological diagnosis and EBV-positive cell density impact survival in Chinese angioimmunoblastic T-cell lymphoma patients.","authors":"Yunfei Shi, Haojie Wang, Yanfei Liu, Mengping Long, Ning Ding, Lan Mi, Yumei Lai, Lixin Zhou, Xinting Diao, Xianghong Li, Weiping Liu, Jun Zhu","doi":"10.21147/j.issn.1000-9604.2023.05.10","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To explore the application of genetic abnormalities in the diagnosis of angioimmunoblastic T-cell lymphoma (AITL) and the reliable pathological prognostic factors.</p><p><strong>Methods: </strong>This study included 53 AITL cases, which were reviewed for morphological patterns, immunophenotypes, presence of Hodgkin and Reed-Sternberg (HRS)-like cells, and co-occurrence of B cell proliferation. The Epstein-Barr virus (EBV)-positive cells in tissues were counted, and cases were classified into \"EBV encoded RNA (EBER) high-density\" group if >50/HPF. Targeted exome sequencing was performed.</p><p><strong>Results: </strong>Mutation data can assist AITL diagnosis: 1) with considerable HRS-like cells (20 cases): <i>RHOA</i> mutated in 14 cases (<i>IDH2</i> co-mutated in 3 cases, 4 cases with rare <i>RHOA</i> mutation), <i>TET2</i> was mutated in 5 cases (1 case co-mutated with <i>DNMT3A</i>), and <i>DNMT3A</i> mutated in 1 case; 2) accompanied with B cell lymphoma (7 cases): <i>RHOA</i> mutated in 4 cases (1 case had <i>IDH2</i> mutation), <i>TET2</i> mutated in 2 cases and <i>DNMT3A</i> mutated in 1 case; 3) mimic peripheral T cell lymphoma, not otherwise specified (5 cases): <i>RHOA</i> mutated in 2 cases (<i>IDH2</i> co-mutated in 1 case), <i>TET2</i> mutated in 3 cases, and <i>DNMT3A</i> mutated in 1 case; 4) pattern 1 (1 case), <i>RHOA</i> and <i>TET2</i> co-mutated. Besides <i>RHOA</i><sup>G17V</sup> (30/35), rare variant included <i>RHOA</i><sup>K18N</sup>, <i>RHOA</i><sup>R68H</sup>, <i>RHOA</i><sup>C83Y</sup>, <i>RHOA</i><sup>D120G</sup> and <i>RHOA</i><sup>G17del</sup>, <i>IDH2</i><sup>R172</sup> co-mutated with <i>IDH2</i><sup>M397V</sup> in one case. There were recurrent mutations of <i>FAT3</i>, <i>PCLO</i> and <i>PIEZO1</i> and genes of epigenetic remodeling, T-cell activation, APC and PI3K/AKT pathway. EBER high-density independently indicated adverse overall survival and progression-free survival (P=0.046 and P=0.008, Kaplan-Meier/log-rank).</p><p><strong>Conclusions: </strong>Over half AITL cases might be confused in diagnosis for certain conditions without mutation data. Targeted exome sequencing with a comprehensive panel is crucial to detect both hot-spot and rare mutation variants for <i>RHOA</i> and <i>IDH2</i> and other recurrent mutated genes in addition to <i>TET2</i> and <i>DNMT3A</i>. EBER high-density independently indicated adverse survival.</p>","PeriodicalId":9882,"journal":{"name":"Chinese Journal of Cancer Research","volume":"35 5","pages":"536-549"},"PeriodicalIF":7.0000,"publicationDate":"2023-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643336/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Cancer Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21147/j.issn.1000-9604.2023.05.10","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: To explore the application of genetic abnormalities in the diagnosis of angioimmunoblastic T-cell lymphoma (AITL) and the reliable pathological prognostic factors.
Methods: This study included 53 AITL cases, which were reviewed for morphological patterns, immunophenotypes, presence of Hodgkin and Reed-Sternberg (HRS)-like cells, and co-occurrence of B cell proliferation. The Epstein-Barr virus (EBV)-positive cells in tissues were counted, and cases were classified into "EBV encoded RNA (EBER) high-density" group if >50/HPF. Targeted exome sequencing was performed.
Results: Mutation data can assist AITL diagnosis: 1) with considerable HRS-like cells (20 cases): RHOA mutated in 14 cases (IDH2 co-mutated in 3 cases, 4 cases with rare RHOA mutation), TET2 was mutated in 5 cases (1 case co-mutated with DNMT3A), and DNMT3A mutated in 1 case; 2) accompanied with B cell lymphoma (7 cases): RHOA mutated in 4 cases (1 case had IDH2 mutation), TET2 mutated in 2 cases and DNMT3A mutated in 1 case; 3) mimic peripheral T cell lymphoma, not otherwise specified (5 cases): RHOA mutated in 2 cases (IDH2 co-mutated in 1 case), TET2 mutated in 3 cases, and DNMT3A mutated in 1 case; 4) pattern 1 (1 case), RHOA and TET2 co-mutated. Besides RHOAG17V (30/35), rare variant included RHOAK18N, RHOAR68H, RHOAC83Y, RHOAD120G and RHOAG17del, IDH2R172 co-mutated with IDH2M397V in one case. There were recurrent mutations of FAT3, PCLO and PIEZO1 and genes of epigenetic remodeling, T-cell activation, APC and PI3K/AKT pathway. EBER high-density independently indicated adverse overall survival and progression-free survival (P=0.046 and P=0.008, Kaplan-Meier/log-rank).
Conclusions: Over half AITL cases might be confused in diagnosis for certain conditions without mutation data. Targeted exome sequencing with a comprehensive panel is crucial to detect both hot-spot and rare mutation variants for RHOA and IDH2 and other recurrent mutated genes in addition to TET2 and DNMT3A. EBER high-density independently indicated adverse survival.
期刊介绍:
Chinese Journal of Cancer Research (CJCR; Print ISSN: 1000-9604; Online ISSN:1993-0631) is published by AME Publishing Company in association with Chinese Anti-Cancer Association.It was launched in March 1995 as a quarterly publication and is now published bi-monthly since February 2013.
CJCR is published bi-monthly in English, and is an international journal devoted to the life sciences and medical sciences. It publishes peer-reviewed original articles of basic investigations and clinical observations, reviews and brief communications providing a forum for the recent experimental and clinical advances in cancer research. This journal is indexed in Science Citation Index Expanded (SCIE), PubMed/PubMed Central (PMC), Scopus, SciSearch, Chemistry Abstracts (CA), the Excerpta Medica/EMBASE, Chinainfo, CNKI, CSCI, etc.